1. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
- Author
-
Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, and Al-Katib AM
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Bryostatins, Female, Humans, Lactones adverse effects, Macrolides, Male, Middle Aged, Treatment Outcome, Antineoplastic Agents therapeutic use, Lactones therapeutic use, Multiple Myeloma drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
Bryostatin 1, a macrocyclic lactone isolated from the marine bryozoan Bugula neritina, is a protein kinase C (PKC) modulator which has shown both preclinical and clinical activity in lymphoid malignancies. We conducted a phase II trial of bryostatin 1 administered at a dose of 120 microg/m2 by 72-h continuous infusion every 2 weeks in patients with relapsed multiple myeloma. Treatment was well tolerated with myalgias constituting the primaray toxicity. There were no responses in nine evaluable patients. The preclinical anti-lymphoid activity is strong enough to support further exploration of bryostatin 1 in different schedules and in combination therapy for multiple myeloma.
- Published
- 2001
- Full Text
- View/download PDF